CPC A61K 38/12 (2013.01) [A61B 5/14546 (2013.01); A61B 5/414 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 38/10 (2013.01); A61K 38/48 (2013.01); A61K 39/3955 (2013.01); G01N 33/6869 (2013.01); G01N 33/6884 (2013.01); G01N 2800/12 (2013.01); G01N 2800/122 (2013.01); G01N 2800/14 (2013.01); G01N 2800/24 (2013.01)] | 19 Claims |
1. A method of treating a subject in need of treatment for a chronic respiratory disorder or other chronic complement-mediated disorder, the method comprising administering multiple doses of a complement inhibitor to the subject by an intravenous, intramuscular, subcutaneous, or respiratory route according to a dosing schedule in which successive doses are administered on average (i) at least 3 weeks after the plasma concentration of the complement inhibitor decreases to no more than 10% of the maximum plasma concentration that was reached after the previous dose; (ii) at intervals such that the subject's complement activation capacity is at least 50% of baseline for on average at least 3 weeks between doses; or (iii) at intervals at least equal to 10 times the terminal plasma half-life of the complement inhibitor when administered by the same route; and
wherein the complement inhibitor comprises a nucleic acid.
|